Waters Corporation (NYSE: WAT) reported first‑quarter 2026 revenue of $1.267 billion, up 91 % year‑over‑year, and an adjusted earnings per share of $2.70, a 20 % increase from the $2.25 adjusted EPS reported in the same quarter of 2025. The revenue beat analyst estimates of $1.20 billion by $0.067 billion, while the EPS beat the consensus of $2.31 by $0.39, a 16.9 % overrun.
The company’s newly acquired Biosciences and Diagnostic Solutions (BDS) business contributed $520 million of revenue in the quarter. While the headline 91 % overall growth includes the BDS contribution, the BDS unit itself grew approximately 7 % year‑over‑year, reflecting early integration gains and a strong start to the combined company’s expanded product portfolio.
Total company adjusted gross margin was 54.7 %, about 200 basis points better than expectations, and adjusted operating margin was 23.6 %, also 200 basis points above forecasts. The margin expansion is driven by a higher mix of high‑margin consumables and service contracts, disciplined cost management, and the continued success of the BDS integration, which has added higher‑margin revenue streams without proportionate cost increases.
Management raised its full‑year 2026 revenue guidance to $6.405 billion–$6.455 billion and adjusted EPS guidance to $14.40–$14.60, up from the prior outlook of $6.30 billion–$6.35 billion and $14.10–$14.30. The upward revision signals confidence in sustained demand across both the core Analytical Sciences division and the newly acquired BDS unit, as well as the ongoing realization of cost and revenue synergies from the February 9, 2026 acquisition.
CEO Udit Batra said the company delivered an “excellent first quarter as a combined company,” citing strong execution discipline, a sharper focus on new product launches, and close collaboration between the Analytical Sciences and BDS divisions. CFO Amol Chaubal highlighted that the adjusted gross margin exceeded expectations by 200 basis points, underscoring effective cost control and a favorable product mix.
Overall, the results demonstrate that Waters is successfully integrating its BDS acquisition while maintaining robust organic growth. The earnings beat, margin expansion, and raised guidance collectively suggest that the company’s strategic initiatives—particularly the 180‑day growth revitalization plan—are delivering tangible financial performance and positioning Waters for continued momentum in the life‑sciences and diagnostics markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.